Mobile

Clinical trial realized in several centers and in several European countries to evaluate a maintenance treatment by lanreotide in patients having neuroendocrine tumors, localized in duodenum or pancre...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-004069-14

Clinical trial realized in several centers and in several European countries to evaluate a maintenance treatment by lanreotide in patients having neuroendocrine tumors, localized in duodenum or pancreas. Lanreotide will be compared with the placebo, and neither the patients nor the doctors will know the treatment taken by the patients

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Phase II: To evaluate the rate of patients alive and progression free at 6 months, assessed by the investigator according to RECIST criteria, version 1.1. Phase III: To assess and compare the Progression Free Survival (PFS) of lanreotide versus placebo according to RECIST criteria (version 1.1, Appendix 3), assessed by the investigator.

Critère d'inclusion

  • Non-resectable duodeno-pancreatic neuroendocrine tumours after first line treatment

Liens